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Acromegaly presents with an enigmatic range of symptoms and comorbidities caused by chronic and progressive growth hormone 
elevations, commonly due to endocrinologic hypersecretion from a pituitary gland tumor. Comprehensive national acromegaly data-
bases have been appearing over the years, allowing for international comparisons of data, although still presenting varying preva-
lence and incidence rates. Lack of large-scale analysis in geographical and ethnic differences in clinical presentation and manage-
ment requires further research. Assessment of current and novel predictors of responsiveness to distinct therapy can lead to multilev-
el categorization of patients, allowing integration into new clinical guidelines and reduction of increased morbidity and mortality as-
sociated with acromegaly. This review compares current data from epidemiological studies and assesses the present-day application 
of prognostic factors in medical practice, the reality of precision therapy, as well as its future prospects in acromegaly, with a special 
focus on its relevance to the South Korean population.
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INTRODUCTION
Acromegaly is a chronic endocrine disease characterized by 
growth hormone (GH) elevation, >95% of the time due to hy-
persecretion by somatotroph cells of a benign pituitary neo-
plasm, or a somatotropinoma [1]. Prolonged excess GH causes 
a plethora of symptoms, stimulating the liver to secrete more in-
sulin-like growth factor 1 (IGF-1) and generating musculoskel-
etal changes, like acral enlargement, increased skin thickness, 
soft tissue hypertrophy, and facial bony deformities may be-
come apparent in such patients [2,3]. At diagnosis most patients 
present with varying systemic comorbidities: diabetes mellitus, 
hypertension, cardiomyopathy, valve disorders, colon polyps, 
goitre, carpal tunnel syndrome, sleep apnea, and sexual distur-
bances [1]. Local tumor mass effects may lead to visual impair-
ment, hypopituitarism, and headache [1]. Cardiovascular, meta-
bolic and oncologic diseases act as principal factors for the esti-
mated 1.5 to 2.5 standardized mortality ratio in patients with ac-
romegaly [3-6]. 
Albeit a rare disease, population-based studies have been able 
to determine the prevalence, ranging from 28 to 134 cases per 
million (cpm) and the incidence, ranging from 1.9 to 11 cpm per 
year [7-19]. Median age at diagnosis is within the fifth decade 
of life, but owing to the small population sizes it is hard to infer 
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differences in gender [20,21]. Majority of the epidemiological 
data has come from Europe [7,9-12,14,16-18], but some repre-
sentative countries, like South Korea in Asia have also made 
such contributions via multi-center [13] and claims database 
studies [15]. Incidence of acromegaly has been on the rise, po-
tentially due to improved diagnostic tools, disease perception 
among physicians and the public, and a real increase in preva-
lence [21]. Despite these developments, prognosis is harmed 
with a median diagnostic delay of 4.5 to 5 years and associated 
comorbidities [21].
Late diagnosis and management are a hurdle that necessitates 
the initiation of precision therapy, or customizing treatment to 
specific patients, in everyday practice. Surgery, acting as first 
line, followed by medical therapy (somatostatin analogues 
[SSAs], GH receptor antagonists, and dopamine agonists 
[DAs]), radiotherapy, radiosurgery (gamma knife surgery), and 
different combinations of each have been shown to result in a 
decrease in morbidity and mortality to general population 
[1,22]. However, cases of resistance to surgical or medical treat-
ment require an integration of clinical and molecular predictors 
to aid in selecting the best tailored treatment. Simultaneous con-
sideration of all predictors, such as the patient’s gender, age, 
pre-operative hormonal levels, tumor size, somatostatin and do-
pamine receptor sensitivity and expression, and signaling path-
way disruption, among others plays a role in improving remis-
sion rates [23-38].
This review compares current data from epidemiological 
studies to judge the reality of precision therapy with a special 
focus on its relevance to the South Korean population. 
EPIDEMIOLOGY IN KOREA AND THE 
WORLD
To this day, epidemiological data of acromegaly is highly vari-
able, as shown by estimations of 20 studies in Table 1. Preva-
lence of acromegaly ranges from 18 to 133 cpm, whereas the 
incidence ranges from 1.9 to 11 cpm/year [7-19,39-45]. 
Highest prevalence of 133 cpm was reported in Iceland, while 
125 cpm was reported in Malta and Belgium both [11,12,41]. 
The sample size in the three studies and the catchment popula-
tion were lower compared to other studies, like in two North 
American studies by Burton et al. [8] and Portocarrero-Ortiz et 
al. [19], which presented over 2,000 cases each and yet, pub-
lished lower prevalence rates. Moreover, the cases in Iceland 
and Malta were compiled over 59 and 12 years periods, respec-
tively, accumulating cases and leading to higher perceived prev-
alence to previously reported studies of shorter length [11,12]. 
Interestingly, despite having one of the largest sample sizes, the 
Mexican national registry reports the lowest prevalence of 18 
cpm, even lower than previously reported data by Kwon et al. 
[13] (28 cpm), Reincke et al. [17] (30 cpm), and Mestron et al. 
[14] (34 cpm) [19]. Colao et al. [1] argued that the increasing 
prevalence in newer studies could be due to improvements in 
the diagnostic approach, or to the availability of larger databas-
es. The former can be explained by higher rates of economic 
growth, improvement and access to healthcare [15]. The latter 
may be inaccurate, as the largest databases present in this re-
view have lower prevalence rates than in Iceland or Malta and, 
yet have discrepancy amongst each other, potentially due to dif-
ference in data collection methods [8,19]. Most studies are 3 to 
5 years in length and if prolonged, could showcase a higher 
prevalence rate. Actual prevalence of this disorder may be high-
er in the rest of the studies, owing to increased patient survival 
and developments in screening, surgical practice, post-opera-
tional follow-up, and medical treatment [1]. 
Furthermore, the highest incidence rate of 11 and 8 cpm/year 
were reported by Burton et al. [8] and Hoskuldsdottir et al. [12], 
respectively, while the majority of other studies present an inci-
dence rate ranging from 3 to 4 cpm/year [10,11,13,15,16,18]. 
Improved awareness among internists and general practitioners, 
rise of social media and the introduction of a universal diagnos-
tic method possibly lead to the increase in incidence rates in re-
cent studies [1,46]. The lowest incidence was reported by Bex 
et al. [7] (1.9 cpm/year) and Mestron et al. [14] (2.1 cpm/year). 
Innovative methods have been recently published by Burton et 
al. [8] and Park et al. [15] about using health insurance data and 
national claims database for the estimation of incidence rates. 
Two 4-year studies, by Kwon et al. [13] (2003 to 2007) and 
Park et al. [15] (2010 to 2013) presented comparable incidence 
rates of 3.6 and 3.9, respectively, which solidified the incidence 
rate of acromegaly in South Korea. As far as this review is con-
cerned, this nation is the only one that has implemented varying 
data collection methods (referral centers and claims database) in 
checking the accuracy of its epidemiological data for this dis-
ease. 
Median age at diagnosis in South Korea is 44.1, following the 
40.5 to 51.7 age range in other studies to date (Table 1) [7-
21,39-46]. It is difficult to establish if there is a difference in 
prevalence of either gender, as there are 10 studies showing a 
higher prevalence in women, including Korea [9,11,13-15,17, 
19,40,43,44], and eight, showcasing the opposite [7,10,16,18, 
39,41,42,45]. Generally, this could indicate an equal occurrence 
Ku CR, et al.
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in either gender (Table 1) [7-21,39-46]. One of the major con-
tributors to high morbidity in acromegaly is the delay in diagno-
sis, which according to recent studies is approximately 5 years 
[12,14,21]. Clinical characteristics and overall comorbidity inci-
dence have been similar among Korean and Western studies 
[1,2,15], but the former showed that females were at higher risk 
of malignancy [2,15]. This also necessitates more widespread 
research on geographical differences in acromegaly-associated 
comorbidities. 
Seeing as how there is insufficient epidemiological data in 
non-European countries, there is a need for international stud-
ies, making a modern comparison of geographical variation, 
ethnicity, sex, healthcare system type, and access to healthcare. 
Establishment of Liege Acromegaly Survey Database across 14 
centers in Europe has been exemplary of international coopera-
tion in epidemiological research, presenting the largest sample 
size to date [44]. Before other continents follow Europe’s foot-
steps, more population-based studies or databases need to be set 
up within nations. North American [8,19,45] or Nordic Europe-
an [10,12,16,18] countries could be next to follow and pool re-
sources, despite each country implementing varying data collec-
tion methods. In regards to Asia, Korea has completed two dif-
ferent types of population-based studies, which have yielded 
similar incidence results. Data about newly established national 
pituitary tumor registries in Iran and Taiwan have been pub-
lished [39,40]. Their future use, if updated with prevalence and 
incidence data, and the appearance of new registries in more 
countries will be a great step for the realization of any ethnic 
and geographical comparisons.
CURRENT TREATMENT APPROACHES 
Historically, surgical excision of pituitary adenomas in a transs-
phenoid surgery (TSS) has been the first-line treatment, being 
the only modality able to reduce morbidity and mortality and 
cause immediate hormonal normalization [1,2]. According to 
thirteen studies from different countries that provided data on 
therapeutic modalities (Table 2), the rates of patients with acro-
megaly that have undergone any pituitary-directed surgery at 
least once as part of their treatment range from 55% to 95% [7, 
11-15,17-19,39-41,43-45], and 44% to 90% for TSS. Taiwan 
and South Korea had highest rates of TSS, the chief treatment 
strategy for 95% and 90% of patients, respectively. Normally, 
the goals of acromegaly treatment include biochemical normal-
ization of GH and IGF-1 levels, tumor mass reduction and sys-
temic comorbidity prevention. Owing to different criteria for re-
mission, follow-up period and treatment modalities, it is diffi-
cult to review the remission rates among different studies, but 
generally, overall surgical cure rate was reported as 40% to 70% 
[1,2]. According to a review by Chen et al. [47], microscopic 
and endoscopic resection of somatotropinomas are both suitable 
approaches for TSS, generating remission rates over 60% at fi-
nal follow-up.
If surgery is contraindicated or if the goals are not achieved, 
then medical therapy is resorted to, as there is a visible trend of 
decreasing use of radiotherapy over time, potentially due to ex-
tensively delayed remission [2,43]. Multiple studies reported 
that radiotherapy (conventional and stereotactic radiosurgery) 
was applied as primary therapy at rates that range between <1% 
and 27% [13,15,17-19,39]. Stereotactic radiotherapy, specifical-
ly gamma knife surgery (GKS), is preferred to conventional ra-
diotherapy, as it normalizes GH and IGF-1 levels more effec-
tively [2] and achieves remission rates of 59% to 65% when 
used as adjuvant treatment for residual or recurrent tumors [48-
50]. Adverse effects of GKS, such as time-dependent hypopitu-
itarism (12.3% to 35% after 5 years), visual disturbance, and 
brain necrosis have been observed in some patients [48-50].
Pharmacotherapy was prescribed as primary treatment in 
2.5% to 45% of patients among the reviewed studies, while the 
majority was reserved for post-operative adjuvant treatment [13, 
15,17-19,39]. To date, SSAs, like octreotide, and lanreotide 
have been the most commonly used drugs, being used at least 
once in a given patient in 6% to 61% of the time [7,12-15,17,41, 
45]. SSA achieve biochemical remission in approximate 55%, 
while tumor size shrinkage is observed in 80% of the cases 
[1,51]. The latter finding makes SSA a suitable pre-operative 
medication for decreasing perioperative morbidity and tumor 
volume, as well as improving surgical outcome [52]. The effect 
on remission rates and recurrence (15% to 84%) after SSA dis-
continuation is highly variable [53], although complete remis-
sion of 4 years after discontinuation was reported in a case [53]. 
As one of the examples of SSA intolerance, SSA-associated de-
terioration in glucose metabolism via inhibition insulin secre-
tion has recently been reported, which can be predicted by plas-
ma glucose 120 minutes post-oral glucose tolerance test 
(OGTT) [35]. Unfortunately, 20% to 25% of acromegaly pa-
tients are resistant to SSA, requiring the use of either DAs or 
growth hormone receptor antagonist (GHRI). To compare the 
effectiveness of DA and GHRI, further investigation is required 
about the medical outcome of patients in different countries. 
Cabergoline is preferred to bromocriptine and is reserved as ei-
ther primary or secondary treatment for patients with mild dis-
Ku CR, et al.
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ease with close to 35% achieving remission [1,51,54]. Pegviso-
mant, the representative GHRI, is also mainly indicated for pa-
tients with resistance to first-line SSA [1,55]. 
Combined medical treatment has been on the rise, as reported 
by Strasburger et al. [56]. SSA and DA combination may return 
IGF-1 levels to normal in over half of the patients [1,54,57]. 
SSA and GHRI combination (SSA+GHRI) may lead to 97% 
and 67.5% normalization in IGF-1 levels in clinical trials and 
5-year surveillance studies, respectively [1,54,57]. The latter 
combination has shown higher rates of liver enzyme elevations, 
implying the need for caution [54]. Furthermore, DA and GHRI 
combination (DA+GHRI) in clinical trials has shown more effi-
cacy in combination, than singularly, introducing them as sub-
stitute for patients intolerant or fully resistant to SSA [54]. 
GHRI monotherapy, SSA+GHRI and DA+GHRI have a similar 
incidence in adverse events, suggesting the high efficacy and 
safety for pegvisomant use [56]. Further prospective research is 
required to provide more evidence about the long-term effec-
tiveness of combined approach to medical therapy. 
Recently, recommendations have been published about im-
plementing adjunctive chemotherapy, temozolomide, in patients 
with serious complications from surgery or radiotherapy, or as 
last-line therapy [54,58]. It is unclear; however, if it is more ef-
fective as monotherapy or in combination. Further research is 
also required in the novel manipulation of chemokine receptor 
CXC chemokine receptor 4 (CXCR4), as a target for anti-neo-
plastic agents, like its antagonist, d-Arg3FC131, which has 
shown to induce apoptosis and inhibit tumor growth in nude 
mice [59-61]. Moreover, gene therapy, being a large field of op-
portunities for the exploration of new treatment methods, is also 
a field of uncertainty in the resultant adverse effects of genetic 
modification, such as inserting SSAs into viral vectors to restrict 
its expression to the pituitary [62]. 
PRECISION THERAPY & PREDICTORS OF 
RESPONSIVENESS
“One treatment for all” concept cannot be applied for the signif-
icant proportion of patients with persistent disease after surgery 
or resistance to medical therapy. Initial selection of SSA and 
subsequent switch to another drug type, judging by the absence 
of disease control, have most perilous disadvantages, when con-
sidering the delay in cure and worsening of patient quality of 
life [22]. Individualized management guidelines [20] can be di-
rected by the advances in translational research, which can yield 
markers of responsiveness to surgery or medical therapy.
Clinical markers include gender [63,64], age [24,63,64], ini-
tial post-operative GH and IGF-1 levels [64], tumor invasion 
[2,64], tumor size [9,24], surgical method [55,63,65,66], sur-
geon experience [63,66], and intensity of T2-weighted magnetic 
resonance imaging (MRI) [23]. Generally, pre-menopausal 
women exhibited poor surgical remission, having more aggres-
sive tumors with higher cavernous sinus invasion rates, lower 
post-operative 75 g OGTT GH normalization and lower long-
term surgical remission rates [63,64]. Old age was associated 
with microadenomas, based on the hypothesis of gradual bio-
logical decline in GH and IGF-1 levels [24]. In South Korea, 
overall surgical remission rates were above 85% in intrasellar 
adenomas and 50% to 70% in extrasellar adenoma [2]. Aggres-
sive surgical resection should be applied in tumors with cavern-
ous sinus invasion that is confined to the medial compartment 
of the internal carotid artery and even in surgically incurable tu-
mors, which can aid remission by minimizing tumor burden and 
aiding effects of adjuvant therapy [66]. Another study also 
showed that it does not increase the risk of postoperative hypo-
pituitarism [63]. Removal of tumor pseudocapsule during trans-
sphenoidal adenomectomy (TSA) improves endocrinological 
remission rates and no increased risk of postoperative hypopitu-
itarism or cerebrospinal fluid rhinorrhea [55,65]. Somatotropi-
nomas present as macroadenomas (>10 mm in diameter) in 
65% to 89% (Table 1) [7-21,39-46], decreasing the possibility 
of complete surgical cure and evoking persistent disease in 
>60% of cases [9]. Gamma knife surgery should be avoided in 
patients with cavernous sinus invasion, owing to the risk of hy-
popituitarism and radiation necrosis [49]. Moreover, somatotro-
pinoma T2 signal hypointensity on MRI was related to better 
clinical outcomes with SSA use [23].
Long-term remission and the selection of the type of adjuvant 
therapy was assessed using the predictive role of immediate and 
1-week post-operative nadir GH levels <1.0 mg/L [67]. A crite-
ria for biochemical remission after surgery of <0.4 mg/L nadir 
GH concentration with 75 g OGTT [68] and a treatment goal of 
<1.0 mg/L [69] random GH concentration have been proposed. 
However, it was shown that neither cut-off values were superior 
in predicting better improvement of metabolic levels in acrome-
galic patients [70]. 
Patients with acromegaly cured with TSA may experience 
GH deficiency (GHD), which may lead to cardiovascular, bone 
and psychological complications. Ku et al. [71] found that the 
presence of a bilateral pituitary tumor and low immediate post-
operative 72-hour GH concentrations (below 0.23 mg/L) pre-
dicted GHD. Administration of recombinant GH has been 
Ku CR, et al.
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shown to improve IGF-1 concentrations and quality of life with-
out deleterious adverse effects [72,73]. Tritos et al. [74], howev-
er, warned of increased cardiovascular complications in GH re-
placement and recommended further investigation on whether it 
was due to previous GH excess in acromegaly. 
Histological markers of remission or resistance to medical 
treatment comprise of granulation pattern [56], expression of 
somatostatin receptor subtype 2a (SSTR2a) [25,26,28], SSTR5 
and dopamine D2 receptor (DR2) [34], Ki-67 index [30], 
β-arrestin, E-cadherin and Raf kinase inhibitor protein (RKIP) 
[31-33]. Tumors with sparse granulation pattern, with hypoin-
tensity on T2-weighted imaging [23] and low SSTR2a expres-
sion [26], exhibited more invasion and little to none GH re-
sponse [26]. SSTR2 and 5 are the receptors on which SSA exert 
their effects, but only the expression of the former has been 
linked to positive predictive response to treatment [25,28]. High 
SSTR2a expression is a predictor for short-term and long-term 
SSA responsiveness by normalizing biochemical levels and re-
ducing tumor size [25,28]. Depletion of SSTR2 expression was 
recognized in SSA pre-treatment groups, showing the loss of 
sensitivity with sustained SSA use [25,28]. Increased DR2 ex-
pression, as the principal receptor subtype expressed in somato-
tropinomas, exhibits better response to DA, while increased 
DR1 or DR5 expression may be related to resistance [34]. Ki-67 
index >3% on histopathological analysis of GH-secreting tu-
mors is associated with increased resistance to treatment [30]. 
Low expression of β-arrestin, E-cadherin, and RKIP have the 
potential to be positive predictors of responsiveness, but further 
research is required to finalize current results [31-33]. 
Molecular markers of long-term remission or cure consist of 
aryl hydrocarbon receptor-interacting protein (AIP) mutation 
and pleomorphic adenoma gene 1 (PLAG1) like zinc finger 1 
(ZAC1) expression [27,29,30], guanine nucleotide binding pro-
tein, alpha stimulating 1 (GNAS1) [29], somatostatin receptor 
subtype 5 (SSTR5) variants, SST5TMD4 and SST5TMD5 and 
single nucleotide polymorphisms, C1004T and T-461C muta-
tions [36-38]. Germline inactivating mutations of AIP, causing 
increased ZAC1 protein expression, are present in 30% of fa-
milial isolated pituitary adenomas cases of acromegaly [29,30]. 
In addition to causing predisposition to more aggressive and 
larger pituitary neoplasms, they tend to cause disease in younger 
patients [29]. Pioneering an animal model for somatotropino-
mas, namely somatotroph specific AIP knock out (sAIPKO) 
mice, allowed for the study of familial acromegaly and adult-
Fig. 1. Flowchart representing current clinical, imaging, histological and molecular predictors, as well as future predictors whose role can be 
finalized with developments in translational research [2,9,23-26,28-38,55,61,63-66]. GH, growth hormone; IGF-1, insulin-like growth fac-
tor-1; MRI, magnetic resonance imaging; SSTR2, somatostatin receptor subtype 2; D2R, dopamine d2 receptor; AIP, aryl hydrocarbon recep-
tor interacting protein; ZAC1, pleomorphic adenoma gene 1 like zinc finger 1; RKIP, Raf kinase inhibitor protein; GNAS1, guanine nucleotide 
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onset GHD [27]. Activating mutations of GNAS1, encoding the 
stimulatory alpha-subunit of protein G, have also been associat-
ed with excess GH secretion in 20% to 30% of McCune-Al-
bright Syndrome patients [29]. The application of the two trun-
cated isoforms of SSTR5, SST5TMD4 and 5, and two of its al-
leles, C1004T and T-461C, in a clinical setting is yet to be final-
ized [36-38]. Another potential predictor of responsiveness to 
treatment could be the increased expression of specific circulat-
ing microRNA (miRNA), such as miR-338-3p, found to act as a 
key promoter of proliferation, migration and invasion in so-
matotropinomas [61]. 
CONCLUSIONS
Nowadays, personalizing management of acromegaly does not 
persist in theory, but is slowly being integrated into reality. One 
of the routes to nearing precision therapy is expanding epidemi-
ological databases: adding much needed geographical and eth-
nic comparisons of patients and sharing treatment approaches, 
especially in Asia. The solidified incidence rate of 3.6 to 3.9 
cpm/year in South Korea [13,15] is not only similar to current 
Western literature [7-12,14,16-19,39-45], but also can be a stan-
dard for epidemiological comparisons of acromegaly among 
other Asian countries. Another route of achieving customization 
of treatment: begin implementing specific predictors of surgery 
and adjuvant treatment responsiveness. Clinical [2,24,55,63-66] 
and imaging [9,23,24] features of the patient, histological and 
molecular characteristics of the tumor [23,25,26,28-30,34] 
(more details in Fig. 1) may be coalesced into clinical guidelines 
[20], while more markers are being researched [29,31-33,36-
38,61]. 
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